Incannex Healthcare announces that it has recruited two highly experienced lead principal investigators for the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of obstructive sleep apnoea. Dr John D Hudson of FutureSearch Trials of Neurology, Austin, Texas and Dr Russell Rosenberg of Neurotrials Research Inc, Atlanta, Georgia. J. Douglas Hudson, MD, is board certified in Neurology and Sleep Medicine. He serves as the Principal Investigator for FutureSearch Trials of Neurology, Austin, Texas. Dr. Rosenberg is currently Chief Science Officer and CEO of NeuroTrials Research in Atlanta, Georgia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IXHL:
- Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
- Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
- Incannex enters a lease for first psychedelic-assisted psychotherapy clinic
- Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
- Incannex announces presentation on results from Phase 1 trial of IHL-675A